



1 October 2020

ASX ANNOUNCEMENT

HFSA Poster Supports HF-Dex in the Management of HF Patients

Brisbane, Australia – ImpediMed Limited (ASX:IPD), a medical software technology company that non-invasively measures, monitors and manages fluid status and tissue composition using bioimpedance spectroscopy (BIS), today announced a poster presentation at the prestigious Heart Failure Society of America (HFSA) Virtual Annual Scientific Meeting, 30 September – 6 October 2020.

The poster combines heart failure patient data from ImpediMed's Heart Failure at Home and IMPEL studies. It demonstrates that a SOZO® with HF-Dex™ assessment greater than 51% serves as a marker for heart failure hospital readmission. The findings showed a statistically significant ($p < 0.05$) difference in median HF-Dex for patients readmitted for heart failure (52.1%) compared to patients not readmitted for heart failure (49.0%) and healthy subjects (44.8%).

“Currently, physical exams, weights, and echo measures are used to assess hydration of heart failure patients, often inadequately,” explained Dr. Andrew Accardi, Emergency Medicine Physician at Scripps Health in San Diego, California and lead author of the poster. “We are extremely encouraged by this data showing SOZO with HF-Dex has the potential to identify high-risk discharges and bend the readmission curve down,” added Dr. Tom Heywood, Heart Failure Cardiologist at Scripps Health and poster co-author.

The patients with class II or III heart failure underwent BIS measurements in an ambulatory care setting or at home using the SOZO technology. The SOZO HF-Dex Heart Failure (HF) Index, which is extracellular fluid (ECF) as a percentage of total body water (TBW), was evaluated for differences across three groups of individuals: HF patients readmitted for acute heart failure (decompensated), HF patients not readmitted (compensated) and healthy adults aged 40+ years. Results show patients readmitted for acute heart failure had a median ECF%TBW of 52.1% supporting HF-Dex greater than 51% is a marker for readmission. The compensated group had a median ECF%TBW of 49.0%, and the healthy population's median was 44.8%.

The SOZO HF-Dex heart failure index is a novel tool for assessing fluid overload in heart failure. Data from this poster, combined with individual patient case reports illustrates additional benefits of SOZO in heart failure patients:

- Differentiating between fluid and tissue-related weight changes
- Tracking response to medication changes
- A marker for readmission when HF-Dex is higher than 51%

“Heart failure readmissions put a substantial cost burden on both public and private payors. We believe our technology can reduce costs associated with managing heart failure patients as well as improve quality of life for heart failure patients and their loved ones,” said Richard Carreon, Managing Director and CEO of ImpediMed. “The data from this poster presentation adds to our growing body of clinical evidence for heart failure, and we anticipate first commercial sales for heart failure in the coming months.”

The poster can be viewed at <https://cattendee.abstractsonline.com/meeting/9156/Presentation/2430> by registering for the HFSA. The poster will also be available on ImpediMed's website at the conclusion of the meeting.

Approved for release by the Managing Director and CEO, Mr Richard Carreon.

Contact Details

Investor relations Contact:

Mike Bassett, ImpediMed
T: +61 407 431 432
E: mbassett@impedimed.com

Media Contact:

Kyahn Williamson, WE Buchan
T: +61 3 9866 4722
E: kwilliamson@weworldwide.com

About ImpediMed

Founded and headquartered in Brisbane, Australia with US and European operations, ImpediMed is a medical software technology company that non-invasively measures, monitors and manages fluid status and tissue composition using bioimpedance spectroscopy (BIS).

ImpediMed produces a family of FDA cleared and CE Marked medical devices, including SOZO® for multiple indications including heart failure, protein calorie malnutrition and lymphoedema, sold in select markets globally.

For more information, visit www.impedimed.com.

About SOZO Digital Health Platform

SOZO, the world's most advanced, noninvasive bioimpedance spectroscopy (BIS) device, delivers a precise snapshot of fluid status and tissue composition in less than 30 seconds. Using ImpediMed's BIS technology, SOZO measures 256 unique data points over a wide spectrum of frequencies from 3 kHz to 1000 kHz. Results are available immediately online for easy data access and sharing across an entire healthcare system. The FDA-cleared, CE-marked and ARTG-listed digital health platform aids in the early detection of secondary lymphedema, provides fluid status for patients living with heart failure, and can be used to monitor and maintain overall health – all on a single device.

For more information, visit: <https://www.impedimed.com/products/sozo/>

About SOZO Fluid Analysis for Heart Failure

The SOZO fluid analysis for heart failure provides an objective measure of fluid overload in heart failure patients. It utilises ImpediMed's HF-Dex™ heart failure index which is a measure of extracellular fluid as a percent of total body water. HF-Dex is presented together with BIS-derived reference ranges for normal fluid volumes, elevated fluid volumes, and fluid overload, which is defined as HF-Dex greater than 51%. When used as part of a clinical assessment of heart failure, SOZO helps differentiate between fluid and tissue-related weight changes to track response to medication changes and to provide a marker for readmission when HF-Dex is higher than 51%.

For more information, visit: <https://www.impedimed.com/healthcare/heart-failure/>

Forward-Looking Statements

This announcement contains or may contain forward-looking statements that are based on management's beliefs, assumptions and expectations and on information currently available to management.

All statements that address operating performance, events or developments that we expect or anticipate will occur in the future are forward-looking statements, including without limitation our expectations with respect to our ability to expand sales and market acceptance in the US and Australia including our estimates of potential revenues, costs, profitability and financial performance; our ability to develop and commercialise new products including our ability to obtain reimbursement for our products; our expectations with respect to our clinical trials, including enrolment in or completion of our clinical trials and our associated regulatory submissions and approvals; our expectations with respect to the integrity or capabilities of our intellectual property position.

Management believes that these forward-looking statements are reasonable as and when made. You should not place undue reliance on forward-looking statements because they speak only as of the date when made. ImpediMed does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. ImpediMed may not actually achieve the plans, projections or expectations disclosed in forward-looking statements. Actual results, developments or events could differ materially from those disclosed in the forward-looking statements.